by TractManager | Jun 28, 2021 | News
On June 25, 2021, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Actemra (tocilizumab; Genentech Inc.) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic...
by TractManager | Jun 23, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on annular closure for the prevention of recurrent lumbar disc herniation (LDH) after lumbar discectomy (LD).Technology Description: Annular closure is a surgical treatment that is performed immediately following an LDH...
by TractManager | Jun 9, 2021 | Emerging Technology Report
Ryplazim is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). Ryplazim is recovered from healthy donor plasma; plasminogen is extracted using a proprietary process. Purified isolated...
by TractManager | Jun 7, 2021 | News
Today the Food and Drug Administration (FDA) approved a biologics license application (BLA) for Aduhelm (aducanumab; Biogen) for the treatment of Alzheimer disease. Aduhelm is an amyloid beta-directed antibody that is administered via intravenous infusion every 4...
by TractManager | Jun 3, 2021 | News
The Food and Drug Administration (FDA) is alerting health care providers that Medtronic has stopped the sale and distribution of the Heartware Ventricular Assist Device (HVAD) System because:There is an increased risk of neurological adverse events and mortality...
Recent Comments